New drug MGC018 tested in tough lung cancer

NCT ID NCT06227546

Ongoing Disease control Sponsor: Georgetown University Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tests the experimental drug MGC018 in 9 people with relapsed or refractory extensive-stage small-cell lung cancer. The main goal is to see if the drug can shrink tumors in at least 25% of patients. Participants receive MGC018 by IV every 28 days until the cancer worsens or side effects become too severe.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: MGC018 (an experimental drug given by IV infusion)
What this could lead to: If it works, this could point toward a new treatment option for people with relapsed small-cell lung cancer.
What could go wrong: This is a very early, small trial with only 9 participants. The drug may not shrink tumors or could cause serious side effects. Success is far from guaranteed.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EXTENSIVE-STAGE SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

EXTENSIVE-STAGE SMALL CELL LUNG CANCER

Contacts and locations

Locations

Lombardi Comprehensive Cancer Center, Georgetown University

Washington D.C., District of Columbia, 20007, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.